PhD in Next-generation CAR T-cell Therapy for Solid Tumours and Prostate Cancer Aarhus University in Denmark

PhD opportunity in next-generation CAR T-cell therapy for solid tumours, with a focus on prostate cancer, at Aarhus University (Department of Biomedicine, Faculty of Health, Aarhus, Denmark).

The project is part of a larger effort to improve solid tumour therapy using engineered immune cells that can seek and kill cancer cells while also delivering a drug to improve tumour penetration and therapeutic potency. The work sits at the intersection of immune cell engineering, drug delivery, cancer therapy, and translational biomedical research. The project is described as fully funded and will involve a highly interdisciplinary research environment with state-of-the-art facilities and international collaborators.

Research activities may include wet-lab molecular biology, mammalian cell culture, drug evaluation, flow cytometry, imaging, and related experimental work. The call notes that collaboration with Karolinska Institutet in Stockholm is important, and a mandatory stay abroad there at the beginning of the project would be advantageous.

Eligibility highlights include a Master’s degree in molecular medicine, molecular biology, biomedical engineering, or a related field; experience with cloning, PCR/qPCR, western blotting, gel electrophoresis, cell culture, and drug/viability assays is preferred. Experience with RNA or peptide therapeutics, in vivo cancer models, and pharmacokinetic/pharmacodynamic evaluations is a plus. Applicants should have strong English skills, analytical ability, independence, attention to detail, and good communication skills for an international team.

Deadline: 3 May 2026, 23:59 CET. Preferred start date: 1 August 2026.

To apply, use the application link and consult Aarhus University’s application guide for predefined PhD projects and mandatory attachments.